ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Multiple Myeloma

Multiple Myeloma

Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant.

The combination of bortezomib and dexamethasone with 160 mg daily ricolinostat, a selective histone deacetylase 6 inhibitor, was well tolerated and active in patients with relapsed/refractory multiple myeloma.

Unfortunately, while survival outcomes with novel therapies have improved, the fraction of patients with multiple myeloma who are cured of their disease remains low. Immune therapies offer the hope for further improvement in outcomes and higher rates of cure.

Here we outline the most promising novel cellular immune strategies for patients with multiple myeloma. In addition, we highlight combinatorial approaches that, it is hoped, will further optimize cellular immunotherapies for myeloma and lead to deep and durable responses and, possibly, even cures.

Among cancer patients with bone metastases, administration of zoledronic acid every 12 weeks did not increase the risk of skeletal events over 2 years compared with the standard dosing of every 4 weeks.

In this interview we discuss the mechanisms of daratumumab, how it is currently used for the treatment of multiple myeloma, and how it might be used in the future.

This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.

Pages

Subscribe to Multiple Myeloma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.